Qiagen and Osmetech Announces Supply Distribution Agreement
News Nov 23, 2005
Qiagen GmbH, a wholly-owned subsidiary of Qiagen N.V. and Osmetech Molecular Diagnostics., a division of Osmetech plc have announced that they have entered into a distribution agreement.
Pursuant to this agreement, Osmetech will incorporate certain preanalytical consumables and technologies from Qiagen into Osmetech microarray-based solutions for use in diagnostic and research applications.
Qiagen's proprietary preanalytical technologies provide reproducibility and efficiency in molecular diagnostics applications.
"We are pleased that Osmetech Molecular Diagnostics has selected Qiagen preanalytical technologies for their eSensor amplification and detection system," said Dr. Frank Krieg-Schneider, Executive Director Strategic Alliances at Qiagen.
"The Osmetech eSensor Platform represents a very attractive platform for molecular diagnostics."
"We are pleased to contribute to their success by providing Qiagen preanalytical solutions which significantly contribute sensitive, robust and reliable nucleic acid testing."
"Osmetech is pleased to enter into this relationship with Qiagen," said Bruce A. Huebner, President of Osmetech Molecular Diagnostics.
"Qiagen's reputation for providing quality preanalytical solutions is well established in the marketplace."
"This step is in line with Osmetech Molecular Diagnostic's goal to provide a quality molecular assay solution to its customers."
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE